SG11202100525SA - Pyrrolopyrimidine itk inhibitors - Google Patents
Pyrrolopyrimidine itk inhibitorsInfo
- Publication number
- SG11202100525SA SG11202100525SA SG11202100525SA SG11202100525SA SG11202100525SA SG 11202100525S A SG11202100525S A SG 11202100525SA SG 11202100525S A SG11202100525S A SG 11202100525SA SG 11202100525S A SG11202100525S A SG 11202100525SA SG 11202100525S A SG11202100525S A SG 11202100525SA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrrolopyrimidine
- itk inhibitors
- itk
- inhibitors
- pyrrolopyrimidine itk
- Prior art date
Links
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862717400P | 2018-08-10 | 2018-08-10 | |
| PCT/US2019/046182 WO2020033955A1 (en) | 2018-08-10 | 2019-08-12 | Pyrrolopyrimidine itk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100525SA true SG11202100525SA (en) | 2021-02-25 |
Family
ID=69405523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100525SA SG11202100525SA (en) | 2018-08-10 | 2019-08-12 | Pyrrolopyrimidine itk inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US11021482B2 (https=) |
| EP (1) | EP3833350A4 (https=) |
| JP (2) | JP7591500B2 (https=) |
| KR (1) | KR102849047B1 (https=) |
| CN (2) | CN119080779A (https=) |
| AU (1) | AU2019317625B2 (https=) |
| BR (1) | BR112021002479A2 (https=) |
| CA (1) | CA3109192A1 (https=) |
| IL (1) | IL280593A (https=) |
| MX (1) | MX2021001558A (https=) |
| PH (1) | PH12021550187A1 (https=) |
| SG (1) | SG11202100525SA (https=) |
| WO (1) | WO2020033955A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| EP3710431A4 (en) | 2017-11-03 | 2021-07-07 | Aclaris Therapeutics, Inc. | SUBSTITUTED PYRROLOPYRIMIDINE-BASED JAK INHIBITORS AND THEIR MANUFACTURING AND USE PROCEDURES |
| WO2020033955A1 (en) * | 2018-08-10 | 2020-02-13 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine itk inhibitors |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| WO2020223728A1 (en) | 2019-05-02 | 2020-11-05 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridines as jak inhibitors |
| CN114787363A (zh) | 2019-10-01 | 2022-07-22 | 恩派瑞安神经科学公司 | 对真菌进行遗传工程化以调节色胺表达 |
| TW202207918A (zh) * | 2020-05-14 | 2022-03-01 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 腸道選擇性ｊａｋ３抑制劑的投與 |
| KR102560138B1 (ko) * | 2020-06-15 | 2023-07-27 | 경북대학교 산학협력단 | 신경교세포 표현형 기반의 siRNA 다중 스크리닝을 통해 선별된 신경교세포 인산화효소의 신경염증 조절 용도 |
| CN114887080B (zh) * | 2020-12-08 | 2023-10-31 | 深圳瑞吉生物科技有限公司 | 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用 |
| CN113350346B (zh) * | 2021-06-01 | 2023-06-27 | 广西医科大学第一附属医院 | 长春新碱在预防或治疗心肌纤维化中的应用 |
| KR20230019801A (ko) * | 2021-08-02 | 2023-02-09 | 한국화학연구원 | 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물 |
| CN113571191A (zh) * | 2021-08-31 | 2021-10-29 | 复旦大学附属中山医院 | 免疫检查点抑制剂相关mace发生风险的预测方法 |
| WO2023110843A1 (en) * | 2021-12-15 | 2023-06-22 | Almirall, S.A. | Heterobicyclic derivatives as itk inhibitors |
| EP4457336A4 (en) | 2021-12-31 | 2026-01-14 | Empyrean Neuroscience Inc | ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS |
| EP4615440A1 (en) * | 2022-11-08 | 2025-09-17 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine compositions for treatment of itk mediated conditions |
| CN116115760A (zh) * | 2022-12-15 | 2023-05-16 | 浙江大学 | Eed抑制剂在制备治疗神经免疫性疾病药物中的应用 |
| WO2025144781A1 (en) * | 2023-12-28 | 2025-07-03 | Aclaris Therapeutics, Inc. | Crystalline polymorph of an itk inhibitor |
| WO2025144783A1 (en) * | 2023-12-28 | 2025-07-03 | Aclaris Therapeutics, Inc. | Methods of synthesizing substituted pyrrolopyrimidine compounds |
| CN117982685B (zh) * | 2024-01-26 | 2025-05-30 | 北京大学人民医院 | 用于骨肉瘤检测的光学分子成像探针及其制备方法和应用 |
| WO2025181247A1 (en) * | 2024-02-28 | 2025-09-04 | Almirall, S.A. | Heterobicyclic derivatives as itk inhibitors |
| WO2025235366A1 (en) * | 2024-05-07 | 2025-11-13 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine compositions for treatment of atopic dermatitis |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2141916T3 (es) | 1993-11-30 | 2000-04-01 | Searle & Co | Pirazolil-bencenosulfonamidas sustituidas para el tratamiento de la inflamacion. |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| WO2000000202A1 (en) | 1998-06-30 | 2000-01-06 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| WO2006127587A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| WO2007007919A2 (en) | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
| EP2123651A4 (en) | 2007-01-12 | 2011-05-04 | Astellas Pharma Inc | CONDENSED PYRIDINE COMPOUND |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体 |
| US9273028B2 (en) | 2010-10-29 | 2016-03-01 | Biogen Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| AU2012295802B2 (en) | 2011-08-12 | 2017-03-30 | Nissan Chemical Industries, Ltd. | Tricyclic heterocyclic compounds and JAK inhibitors |
| EP2788000B1 (en) | 2011-12-06 | 2018-05-30 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| US9206188B2 (en) * | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
| GB2515785A (en) * | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
| MX368464B (es) * | 2013-12-05 | 2019-10-02 | Pfizer | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo. |
| EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| CR20160525A (es) | 2014-05-14 | 2016-12-20 | Pfizer | Pirazolopiridinas y pirazolopirimidinas |
| WO2016000615A1 (en) * | 2014-07-02 | 2016-01-07 | Sunshine Lake Pharma Co., Ltd. | Heteroaryl compounds and pharmaceutical applications thereof |
| CN105712998B (zh) * | 2014-12-05 | 2019-12-13 | 上海润诺生物科技有限公司 | 氮杂吲哚类衍生物、其制备方法及其在医药上的应用 |
| CA2973597A1 (en) * | 2015-01-23 | 2016-07-28 | Confluence Life Sciences, Inc. | Heterocyclic itk inhibitors for treating inflammation and cancer |
| US10703756B2 (en) * | 2015-05-01 | 2020-07-07 | Pfizer Inc. | Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof |
| WO2017097224A1 (zh) | 2015-12-11 | 2017-06-15 | 四川科伦博泰生物医药股份有限公司 | 氮杂环丁烷衍生物、其制备方法及用途 |
| RU2714206C1 (ru) * | 2016-06-30 | 2020-02-13 | Даевунг Фармасьютикал Ко., Лтд. | Пиразолопиримидиновые производные в качестве ингибитора киназы |
| TW201811795A (zh) * | 2016-08-24 | 2018-04-01 | 美商亞闊股份有限公司 | 胺基－吡咯并嘧啶酮化合物及其用途 |
| EP3710431A4 (en) | 2017-11-03 | 2021-07-07 | Aclaris Therapeutics, Inc. | SUBSTITUTED PYRROLOPYRIMIDINE-BASED JAK INHIBITORS AND THEIR MANUFACTURING AND USE PROCEDURES |
| US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
| WO2020033955A1 (en) * | 2018-08-10 | 2020-02-13 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine itk inhibitors |
| CA3123596A1 (en) | 2018-12-19 | 2020-06-25 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
| WO2020223728A1 (en) | 2019-05-02 | 2020-11-05 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridines as jak inhibitors |
| CA3150975A1 (en) | 2019-06-10 | 2020-12-17 | Incyte Corporation | Topical treatment of vitiligo by a jak inhibitor |
| WO2021022178A1 (en) | 2019-07-31 | 2021-02-04 | Aclaris Therapeutics, Inc. | Substituted sulfonamide pyrrolopyridines as jak inhibitors |
-
2019
- 2019-08-12 WO PCT/US2019/046182 patent/WO2020033955A1/en not_active Ceased
- 2019-08-12 EP EP19846283.0A patent/EP3833350A4/en active Pending
- 2019-08-12 KR KR1020217007377A patent/KR102849047B1/ko active Active
- 2019-08-12 CA CA3109192A patent/CA3109192A1/en active Pending
- 2019-08-12 JP JP2021531626A patent/JP7591500B2/ja active Active
- 2019-08-12 CN CN202411055491.XA patent/CN119080779A/zh active Pending
- 2019-08-12 US US16/538,354 patent/US11021482B2/en active Active
- 2019-08-12 SG SG11202100525SA patent/SG11202100525SA/en unknown
- 2019-08-12 CN CN201980066579.2A patent/CN112823005B/zh active Active
- 2019-08-12 BR BR112021002479-4A patent/BR112021002479A2/pt not_active IP Right Cessation
- 2019-08-12 AU AU2019317625A patent/AU2019317625B2/en active Active
- 2019-08-12 MX MX2021001558A patent/MX2021001558A/es unknown
-
2021
- 2021-01-25 PH PH12021550187A patent/PH12021550187A1/en unknown
- 2021-02-02 IL IL280593A patent/IL280593A/en unknown
- 2021-04-21 US US17/236,531 patent/US11820775B2/en active Active
-
2023
- 2023-10-24 US US18/383,301 patent/US12297203B2/en active Active
-
2024
- 2024-11-18 JP JP2024200937A patent/JP2025037892A/ja active Pending
-
2025
- 2025-04-18 US US19/182,994 patent/US20260035373A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021001558A (es) | 2021-04-28 |
| PH12021550187A1 (en) | 2022-02-14 |
| IL280593A (en) | 2021-03-25 |
| KR20210044822A (ko) | 2021-04-23 |
| WO2020033955A1 (en) | 2020-02-13 |
| CN119080779A (zh) | 2024-12-06 |
| KR102849047B1 (ko) | 2025-08-22 |
| EP3833350A1 (en) | 2021-06-16 |
| CN112823005A (zh) | 2021-05-18 |
| US11021482B2 (en) | 2021-06-01 |
| JP7591500B2 (ja) | 2024-11-28 |
| JP2021534244A (ja) | 2021-12-09 |
| US20200048262A1 (en) | 2020-02-13 |
| US11820775B2 (en) | 2023-11-21 |
| AU2019317625A1 (en) | 2021-02-18 |
| US20260035373A1 (en) | 2026-02-05 |
| US12297203B2 (en) | 2025-05-13 |
| US20220348579A1 (en) | 2022-11-03 |
| BR112021002479A2 (pt) | 2021-07-27 |
| CN112823005B (zh) | 2024-08-20 |
| EP3833350A4 (en) | 2022-05-18 |
| JP2025037892A (ja) | 2025-03-18 |
| US20240132505A1 (en) | 2024-04-25 |
| AU2019317625B2 (en) | 2025-02-27 |
| CA3109192A1 (en) | 2020-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202100525SA (en) | Pyrrolopyrimidine itk inhibitors | |
| SG11202106520VA (en) | Kif18a inhibitors | |
| ZA201905811B (en) | Novel inhibitors | |
| IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| IL275331A (en) | Quinazolinones as PARP14 inhibitors | |
| GB201705971D0 (en) | Inhibitor compounds | |
| IL274207A (en) | Aminoimidazopyridazines as kinase inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| SG11202102379XA (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
| IL281599A (en) | TYK2 kinase inhibitors | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| GB201721465D0 (en) | Inhibitors | |
| HK40055501A (en) | Pyrrolopyrimidine itk inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201914388D0 (en) | Kinase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors | |
| GB201720145D0 (en) | Inhibitor compounds | |
| GB201716867D0 (en) | MAP4K4 inhibitors |